PUT/VERTEX PHARMACEUTICALS/500/0.1/16.01.26 | Real-time BOERSE MUENCHEN 12:26:04 2024-07-01 pm EDT | ||
| 6.34 EUR | -0.78% |
|
| Current month | -13.53% | ||
| 1 month | -13.30% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 24-07-01 | 6.34 | -0.78% |
| 24-06-28 | 6.39 | +1.11% |
| 24-06-27 | 6.32 | -0.94% |
| 24-06-26 | 6.38 | -0.62% |
| 24-06-25 | 6.42 | +1.74% |
Real-time BOERSE MUENCHEN
Last update July 01, 2024 at 12:26 pm EDT
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | PUT |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | Goldman Sachs |
| WKN | GG24AA |
| ISIN | DE000GG24AA9 |
| Date issued | 2024-01-23 |
| Strike | 500 $ |
| Maturity | 2026-01-16 (564 Days) |
| Parity | 10 : 1 |
| Emission price | 7.99 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 10.94 € |
|---|---|
| Lowest since issue | 5.86 € |
| Spread | 0.2 € |
| Spread % | 3.06% |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
32
Last Close Price
468.7
USD
Average target price
468.3
USD
Spread / Average Target
-0.10%
- Stock Market
- Warrants
- Warrant
